Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
New drugs targeting calcitonin gene-related peptide for the management of migraines28
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder27
A review of phase II and III drugs for the treatment and management of endometriosis26
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia21
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review18
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials18
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?18
Emerging medicines to improve the basic defect in cystic fibrosis17
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials16
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia15
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?15
Emerging injectable therapies for osteoarthritis12
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape12
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials12
Emerging biological treatments for asthma11
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms11
Emerging drugs for the treatment of herpetic keratitis10
A review of emerging factor XI inhibitors9
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials9
Cannabinoid treatment for the symptoms of autism spectrum disorder9
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder8
Expert opinion on emerging drugs for lung chronic graft-versus-host disease8
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria8
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?8
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials8
Emerging antiviral therapies and drugs for the treatment of influenza7
How will tovorafenib change our treatment of pediatric low-grade glioma?7
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials7
Recent advances in immune-based approaches for the treatment of esophagogastric cancer7
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma7
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials7
Correction7
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion7
Emerging tyrosine kinase inhibitors for head and neck cancer7
Emerging drugs for the treatment of irritability associated with autism spectrum disorder7
0.053843021392822